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HYPERTENSION AND RENAL DISEASE
Introduction
binders to reduce this condition was discussed, and shouldThis Supplement to Kidney International contains the
prove useful to the practice of nephrology. Several lec-proceedings of the Third International Conference on Hy-
tures underscored the role of strict blood pressure con-pertension and the Kidney. The Conference, held in Ma-
trol with the antiproteinuric and renoprotective renin-drid in February 2002, was organized by the Department
angiotensin system (RAS) blocking drugs, angiotensinof Nephrology of the Hospital General, Universitario
converting enzyme (ACE) inhibitors, and angiotensinGregorio Maran˜o´n, under the sponsorship of the Spanish
receptor blockers. Persistent uncontrolled hypertensionSociety of Nephrology, Spanish Society of Hypertension,
and severe proteinuria were shown to be the strongestEuropean Renal Association–European Dialysis and
predictors of progression of chronic renal disease.Transplant Association, and European Society of Hyper-
The results of the latest clinical trials in type 2 diabetictension.
patients with renal disease were also discussed. One con-The purpose of this Conference was to inform the
clusion from these studies is that patients with diabeticnephrology community of recent advances in the study
nephropathy should receive therapy with an agent thatof vascular disease as a cause and consequence of renal
blocks the RAS, to prevent the development and haltdisease. To further this objective, a sizable number of
the progression of renal disease in diabetic patients. Hy-international scientific personalities were assembled, all
pertension associated with end-stage renal disease andof them renowned experts in the field. We sincerely thank
the effects of different therapies—hemodialysis, chronicall who participated for their presence and contributions.
peritoneal dialysis and renal transplantation—was theUnfortunately, this Conference missed the company
last topic considered at the Conference. Blood pressureof its most important promoter, Professor Fernando Val-
control is essential for survival in dialysis patients, andderra´bano, who died some months earlier in Madrid at
hypertension is also a risk factor for graft survival inthe age of 59 years. The Guest Editors wish to dedicate
transplant patients. Recent evidence showing that trans-this issue of the Proceedings of the Conference to his
forming growth factor- (TGF-) and RAS are involvedmemory.
in the pathogenesis of chronic allograft nephropathy sug-Several of the topics discussed at this Conference con-
gests a significant role for angiotensin II blocking drugscerned the effects of drugs on the progression of renal
in preventing the chronic allograft nephropathy that is
disease. Diabetes and its impact on the pathogenesis of the most frequent cause of transplant loss.
renal failure, and the factors associated with the worsen- We are grateful to all of the distinguished contributors
ing and acceleration of the disease in such patients also to this Conference for both their lectures at the event
were explored in depth. Because diabetes has become and their articles that comprise this Supplement. We
the leading cause of end-stage renal failure worldwide, thank Merck Sharpe & Dohme, Astra Zeneca of Spain,
the information provided was extremely relevant to prac- Bayer, Genzme, Fujisawa, and Wyeth Lederle for their
titioners who deal with these types of patients. Another generous contributions that support the publication of
topic examined was the issue of cardiac calcification in these proceedings. Finally, we express our deepest grati-
renal failure patients. New information about the role tude for the interest and leadership shown by the Editor
of hyperphosphatemia and the use of new phosphate of Kidney International, Dr. Saulo Klahr, who kindly
favored the publication of this special issue.
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